Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances, and intermediates. Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture, and market pharmaceutical products, pharmaceutical substances, and Intermediates.
The company has evolved from its humble beginnings as Alembic Chemical Works in 1907 to become one of India's most prominent pharmaceutical manufacturers. Alembic Pharmaceuticals Ltd. initially began as Alembic Chemical Works where it started manufacturing tincture and alcohol at its unit at Vadodara in 1907. Over the decades, the company has expanded its operations significantly, becoming a major player in both domestic and international pharmaceutical markets.
Alembic Pharmaceuticals is a leading manufacturer and Supplier of Generic Medicine in India. It is also termed to be a market leader in the macrolides segment of anti-infective drugs in India.
The company operates across multiple therapeutic areas and product segments. The company's products include oral solids, oncology OSD, general and oncology injectables, generic formulations, and ophthalmic and dermatology products. It offers products for therapeutic areas of cardiovascular, analgesics, gynecology, cough and cold, gastroenterology, ophthalmology, anti-diabetics, orthopedics, urology, and dermatological therapies.
The company operates in India, the US, Canada, Brazil, Australia, and South Africa. APL is headquartered in Vadodara, Gujarat, India. The company has established a robust manufacturing infrastructure with facilities strategically located across India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India.
The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh, manufactures formulations for the domestic and non-regulated export market. The company's state-of-the-art research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the US FDA.
The company has a state-of-the-art Research Centre at Vadodara. Alembic has two research and development (R&D) centers which have been well supported by Alembic for its growth initiatives. The company has spent much of its capital on R&D, with the majority of expenses on R&D for its markets in the US.
The company's commitment to research and development is evident from its substantial investments in this area. For the FY2015-2016, Alembic Pharmaceuticals invested ₹346 Crore in R&D alone with 470 ongoing projects. The company has 3 R&D and 5 manufacturing facilities.
In 2011, the equity shares of Alembic Pharmaceuticals Ltd. were listed on the Bombay Stock Exchange and National Stock Exchange of India. On September 20, 2011, the equity shares of Alembic Pharmaceuticals, post its demerger from Alembic Ltd., got listed on the Bombay Stock Exchange where it is a constituent of the BSE 500 index and on the National Stock Exchange of India where it is a constituent of the Nifty 500 index.
As of current market data, the Market Cap is ₹19,670 Crore. The company has shown consistent performance with Revenue: ₹6,672 Crore and Profit: ₹582 Crore for FY25. Promoter holding in Alembic Pharmaceuticals Ltd has gone up to 69.67% as of March 2025 from 69.61% as of June 2024.
For Q4 FY25, the company reported mixed results:
- Net Profit: ₹157 Crore, a 12% decrease from ₹178 Crore in Q4 FY24.
- Revenue from Operations: ₹1,770 Crore, up 17% from ₹1,516.98 Crore in Q4 FY24.
- EBITDA: ₹286 Crore, a 9% increase year-on-year.
- EBITDA Margin: 16%, compared to 17.1% in the same period last year.
The company has declared a Final dividend of ₹11 per equity share of face value ₹2, subject to shareholder approval at the upcoming AGM. Additionally, Alembic Pharmaceuticals Ltd. has an upcoming dividend of ₹11.00 per share due on July 29, 2025.
The company has been actively pursuing strategic acquisitions to expand its market presence. In 2007, Alembic acquired the entire non-oncology formulation business of Dabur Pharma Ltd. for ₹159 Crore. This acquisition was termed to be one of the largest in the domestic pharma sectors during the year 2007.
Recently, Alembic's subsidiary acquires Utility Therapeutics for $12 million to market FDA-approved and pipeline UTI drugs in the US. This acquisition demonstrates the company's commitment to expanding its presence in the US market and strengthening its product portfolio.
In 2016, Forbes included Alembic Pharmaceuticals in 'India's Super 50 Companies 2016' list. The company has also been recognized as a Great Place to Work certified organization, reflecting its commitment to employee satisfaction and workplace culture.
Looking ahead, Alembic Pharmaceuticals continues to focus on expanding its global footprint while maintaining its strong position in the Indian market. Alembic Pharmaceuticals aims to focus on cost optimization and operational efficiency to improve margins. The company plans to invest in technology and process improvements to mitigate the impact of rising input costs. Additionally, expanding its product portfolio and exploring new markets are on the agenda to drive future growth.
The company's diversified business model, strong R&D capabilities, and global manufacturing presence position it well for continued growth in the competitive pharmaceutical industry. With its established market leadership in key therapeutic segments and ongoing investments in innovation, Alembic Pharmaceuticals remains well-positioned to capitalize on opportunities in both domestic and international markets.
